Clinical Trial Update: Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating melphalan and dexamethasone with or without bortezomib in previously untreated systemic light-chain amyloidosis (primary systemic amylo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Amyloidosis
• Systemic Light Chain Amyloidosis

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Melphalan (Melphalan)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Light Chain Deposition Disease, Primary Systemic Amyloidosis | Phase 3 | Status: COMPLETED | Results posted: 2014-11-26